Artesunate-erythropoietin combination for murine cerebral malaria treatment.
暂无分享,去创建一个
Stéphane Picot | J. Ferrandiz | Anne-Lise Bienvenu | A. Bienvenu | S. Picot | Karine Kaiser | K. Kaiser | Christine Latour | Josette Ferrandiz | Christine Latour
[1] E. Riley,et al. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. , 2002, Microbes and infection.
[2] P. Newton,et al. Misattribution of central nervous system dysfunction to artesunate. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] P. Ghezzi,et al. Erythropoietin as an antiapoptotic, tissue-protective cytokine , 2004, Cell Death and Differentiation.
[4] Z. Erbayraktar,et al. Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.
[5] E. Ashley,et al. Artemisinin-based combinations , 2005, Current opinion in infectious diseases.
[6] P. Lewczuk,et al. Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial , 2002, Molecular medicine.
[7] Mary E. Wilson. Parenteral artesunate for treatment of severe malaria , 2006, Current infectious disease reports.
[8] K. Marsh,et al. Clinical features and pathogenesis of severe malaria. , 2004, Trends in parasitology.
[9] F. Abboud,et al. Neurocardiovascular regulation in mice: Experimental approaches and novel findings , 2003, Clinical and experimental pharmacology & physiology.
[10] D. Kwiatkowski,et al. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. , 1996, The Journal of infectious diseases.
[11] B. Ogutu,et al. Cerebral Malaria , 2003, CNS drugs.
[12] P. Ringwald,et al. Comparison of a SYBR Green I-Based Assay with a Histidine-Rich Protein II Enzyme-Linked Immunosorbent Assay for In Vitro Antimalarial Drug Efficacy Testing and Application to Clinical Isolates , 2007, Antimicrobial Agents and Chemotherapy.
[13] S. Vilaró,et al. Erythropoietin protects the in vitro blood–brain barrier against VEGF‐induced permeability , 2003, The European journal of neuroscience.
[14] K. Maiese,et al. Erythropoietin involves the phosphatidylinositol 3‐kinase pathway, 14‐3‐3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity , 2007, British journal of pharmacology.
[15] S. Ranque,et al. Risk factors for severe malaria in Bamako, Mali: a matched case-control study. , 2004, Microbes and infection.
[16] N. Hunt,et al. Cerebral malaria -- a neurovascular pathology with many riddles still to be solved. , 2004, Current neurovascular research.
[17] J. Golenser,et al. Conventional and experimental treatment of cerebral malaria. , 2006, International journal for parasitology.
[18] L. Jolliffe,et al. Erythropoietin Concentrations in Cerebrospinal Fluid of Nonhuman Primates and Fetal Sheep following High-Dose Recombinant Erythropoietin , 2004, Neonatology.
[19] K. Maitland,et al. Research priorities in the management of severe Plasmodium falciparum malaria in children , 2006, Annals of tropical medicine and parasitology.
[20] J. Golenser,et al. Current perspectives on the mechanism of action of artemisinins. , 2006, International journal for parasitology.
[21] W. Trager,et al. Human malaria parasites in continuous culture. , 1976, Science.
[22] L. F. Fajardo,et al. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. , 1987, Science.
[23] P. Ghezzi,et al. Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[24] A. Cerami,et al. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. , 2006, Kidney international.
[25] L. Rénia,et al. Experimental models of cerebral malaria. , 2005, Current topics in microbiology and immunology.
[26] A. Buguet,et al. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. , 2006, The Journal of infectious diseases.
[27] Charles R. Newton,et al. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. , 1998, Pharmacology & therapeutics.
[28] Deborah J. Nicolls,et al. Neurotoxicity due to antimalarial therapy associated with misdiagnosis of malaria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] P. Ghezzi,et al. Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis , 2003, The Journal of experimental medicine.
[30] A. Cerami,et al. Emerging biological roles for erythropoietin in the nervous system , 2005, Nature Reviews Neuroscience.
[31] A. Gbadoé,et al. Prise en charge du paludisme grave de l'enfant au centre hospitalier régional de Tsévié (Togo) , 2006 .
[32] R. Koene,et al. [Recombinant human erythropoietin]. , 1988, Nederlands tijdschrift voor geneeskunde.
[33] P. Lewczuk,et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] G. Grau,et al. Pathogenesis of Cerebral Malaria: Recent Experimental Data and Possible Applications for Humans , 2001, Clinical Microbiology Reviews.
[35] R. Micciolo,et al. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. , 1995, The Journal of infectious diseases.
[36] Qigui Li,et al. Risk Assessment and Therapeutic Indices of Artesunate and Artelinate in Plasmodium berghei–Infected and Uninfected Rats , 2005, International journal of toxicology.
[37] H. Ehrenreich,et al. The Brain Erythropoietin System and its Potential for Therapeutic Exploitation in Brain Disease , 2006, Journal of neurosurgical anesthesiology.
[38] Arjen Dondorp,et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial , 2005, The Lancet.
[39] D. Parry,et al. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[40] M. Herrmann,et al. Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease , 2004, Metabolic Brain Disease.
[41] B. Ryffel,et al. Oral artesunate prevents Plasmodium berghei Anka infection in mice. , 2003, Parasitology international.
[42] Imelda Bates,et al. Antimalarial Bioavailability and Disposition of Artesunate in Acute Falciparum Malaria , 2000, Antimicrobial Agents and Chemotherapy.
[44] P. Ghezzi,et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Tait,et al. Recombinant human erythropoietin: purification and analysis of carbohydrate linkage. , 1988, Archives of biochemistry and biophysics.
[46] K. Maiese,et al. Erythropoietin on a Tightrope: Balancing Neuronal and Vascular Protection between Intrinsic and Extrinsic Pathways , 2004, Neurosignals.
[47] H. Webster,et al. Plasmodium falciparum-Based Bioassay for Measurement of Artemisinin Derivatives in Plasma or Serum , 2004, Antimicrobial Agents and Chemotherapy.
[48] Qigui Li,et al. Toxicokinetics and Hydrolysis of Artelinate and Artesunate in Malaria-Infected Rats , 2005, International journal of toxicology.
[49] C. Newton,et al. Pathogenesis, clinical features, and neurological outcome of cerebral malaria , 2005, The Lancet Neurology.
[50] V. J. Venema,et al. VEGF-induced permeability increase is mediated by caveolae. , 1999, Investigative ophthalmology & visual science.